Sona Nanotech Approved For Clinical Trials of Saliva-Based COVID-19 Rapid Test
Sona Nanotech (CSE: SONA) has been approved to begin clinical trials. The company this morning announced that Health Canada has granted it Investigation Testing Authorization for its Saliva C-19 Rapid Test.
The clinical trials to be conducted will be focused on the firms saliva-sample based rapid COVID-19 antigen test. The trials are to be conducted with Humber River Hospital, which is located in Toronto. Trials are to begin once the firm receives final ethics review board sign-offs for the firms trial protocol, which is expected to occur shortly.
The objective of the trial is to determine the clinical performance of the saliva sample rapid test as compared to that of an RT-PCR test in symptomatic patients. Analytical validation will then be required after testing to support any regulatory submissions for final approval of the test.
Sona Nanotech last traded at $1.65 on the CSE.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
